中国家庭的营养消费也在经历一场追求科学营养的"升维变革"。今年京东11.11，有超2500个营养保健品牌成交 额同比翻倍，近100个营养保健细分品类成交额同比增长超100%。正值秋冬滋补时节，阿胶制品、组合养生茶等 滋补品类成交额同比超200%，镁、生物素、维生素D等维生素矿物质品类成交额同比增长超150%。 健康消费再创新高 超7000个品牌成交额同比翻倍 随着全民健康消费意识进一步提高，用户对健康管理的主动性显著增强，并呈现出多元化、精细化与智能化等 消费趋势。 今年京东11.11，有超2500个医药品牌成交额同比翻倍；原研创新药品类成交额同比翻倍，再一次印证了京东健 康提高原研药、新特药可及性的价值。时值秋冬交替，感冒等呼吸道疾病高发，购买家庭常备药的新用户数同 比翻倍。 2025年京东11.11收官，各类健康消费和健康服务的数据再创新高，超7000个品牌成交额同比翻倍。在此期间， 京东健康打造"健康免单明星天团"，连续22天接力送百万免单福利；京东健康采销直播间11.11成交额也同比增 长超100%，进一步激发健康消费新活力。 这个京东11.11，京东健康以"超级医药供应链"为基础设施，深度融合专业医 ...

本报讯 （记者梁傲男）2025年京东11.11收官，各类健康消费和健康服务的数据再创新高，超7000个品牌成交额同比翻 倍。在此期间，京东健康打造"健康免单明星天团"，连续22天接力送百万免单福利；京东健康采销直播间11.11成交额也同比增 长超100%，进一步激发健康消费新活力。 这个京东11.11，京东健康以"超级医药供应链"为基础设施，深度融合专业医疗健康服务，以及医疗AI大模型等数智技术， 成为赋能大健康产业的强大引擎，不仅带动品类销售持续增长，更是构建起多方共赢的产业生态，进一步巩固"线上健康消费 第一入口"优势地位。 恰逢第八届中国国际进口博览会，京东健康还与来自11个国家的21个顶尖医药健康品牌达成合作，数量和规模均创历史新 高，成为跨国品牌将进博会展品转化为中国市场商品的"加速器"和"服务商"。 中国家庭的营养消费也在经历一场追求科学营养的"升维变革"。今年京东11.11，有超2500个营养保健品牌成交额同比翻 倍，近100个营养保健细分品类成交额同比增长超100%。正值秋冬滋补时节，阿胶制品、组合养生茶等滋补品类成交额同比增 长超200%，镁、生物素、维生素D等维生素矿物质品类成交额同比增长 ...

Group 1 - The healthcare industry in China is poised to become one of the largest industries due to factors such as aging population, chronic disease prevalence, rising health awareness, and the national health strategy [3][4] - The shift from a "disease-centered" approach to a "health-centered" model is necessary, emphasizing preventive care and comprehensive health management [4][5] - Traditional healthcare business models are undergoing disruptive reconstruction, with a need for new value creation models and organizational structures [5][6] Group 2 - The healthcare industry is returning to its public welfare roots, with a focus on genuine health outcomes rather than profit-driven motives [6][7] - AI and emerging technologies are expected to create a divide in the industry, favoring institutions that can integrate technology effectively [7][8] - Market-oriented AI applications are more sustainable than government procurement models, driving efficiency and innovation in healthcare services [8][9] Group 3 - Commercial health insurance is becoming a crucial component of the multi-tiered healthcare system, with potential market value exceeding trillions [9][10] - Private healthcare institutions are expected to undergo structural upgrades rather than decline, focusing on quality over quantity [10][11] - Public hospitals are facing increased scrutiny and cost control measures, leading to heightened survival pressures for third-party service providers [11][12] Group 4 - There is a fundamental shift in public health consciousness, moving from treatment to prevention and self-management, particularly among younger and older demographics [12]

Group 1: Company Overview and Strategy - Guoxin Health is focused on building a multi-level medical security system based on the "1+3+N" framework, addressing the needs for supplementary insurance and the pain points in commercial health insurance [2] - The company is implementing a "Digital Intelligence Innovation" strategy and has initiated the "AI in ALL" action to enhance its data processing capabilities and integrate AI technology across various medical fields [3] Group 2: Financial Performance - In 2024, the company achieved a revenue of approximately 356.9 million RMB, representing a year-on-year growth of 8.11%, while the net profit was approximately -11.5 million RMB, showing a reduction in losses by 85.72% [12] - The company’s revenue in 2024 compared to 2020 increased by about 150 million RMB, a growth rate of approximately 72% [8] Group 3: Market Position and Growth Potential - Guoxin Health has served over 70 regions under the DRG payment reform and maintains a leading market share in the DIP payment implementation across 40 regions [8] - The company is actively expanding its innovative services in health management, commercial insurance, and pharmaceutical innovation, which are expected to be new growth points [10] Group 4: Shareholder Engagement and Future Plans - As of March 31, 2025, the company had 70,199 shareholders, indicating a broad base of investor support [6] - The major shareholder plans to increase their stake in the company by investing between 100 million RMB and 200 million RMB within the next six months [13]